| 前收盘价格 | 0.290 |
| 收盘价格 | 0.290 |
| 成交量 | 5,001,735 |
| 平均成交量 (3个月) | 4,258,441 |
| 市值 | 341,945,856 |
| 价格/销量 (P/S) | 1.32 |
| 股市价格/股市净资产 (P/B) | 2.76 |
| 52周波幅 | |
| 利润日期 | 29 Jul 2024 - 2 Aug 2024 |
| 营业利益率 (TTM) | -1,353.42% |
| 稀释每股收益 (EPS TTM) | -0.040 |
| 季度收入增长率 (YOY) | -4.90% |
| 总债务/股东权益 (D/E MRQ) | 0.84% |
| 流动比率 (MRQ) | 18.25 |
| 营业现金流 (OCF TTM) | -34.82 M |
| 杠杆自由现金流 (LFCF TTM) | -23.25 M |
| 资产报酬率 (ROA TTM) | -16.67% |
| 股东权益报酬率 (ROE TTM) | -26.21% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | IMMUTEP FPO [IMM] | - | - |
AIStockmoo 评分
0.8
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.75 |
|
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.04% |
| 机构持股比例 | 38.95% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合